GSK: 1 director

A director at GSK sold 29,763 shares at 1,544p and the significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members along...

MFN Drug Pricing - Impact and Implementation (Thematic, 5pgs)

Ahead of today’s signing of an Executive Order to introduce a Most Favoured Nation approach to drug pricing in the US, we show that net pricing in the EU is c.50% lower than in the US & which companies have most to lose from MFN. We also show that, in reality,

US Tariffs - Broad Tariffs are Highly Unlikely (7pgs)

Following a number of recent events, we discuss in this note what we think is the most likely outcome for the Pharma industry. We show that broad based tariffs on drugs are highly unlikely, that even if it were to happen, the impact of a 20% tariff is

Ströer SE & Co. KGaA : Un T3 moins dynamique qu'attendu mais les fondamentaux restent toujours identiques et solides

thyssenkrupp nucera : On track to deliver of FY 2024-25 guidance, but next FY should be softer due to continued low new orders

Glanbia : H1 results above expectations. FY guidance for EPS upgraded on better revenue growth for GPN and improved margin for H&N